Stock Market Reviews

AURA (Aura Biosciences, Inc.) News

Get the latest news, insights, and market updates on AURA (Aura Biosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
  BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025. “I am pleased to welcome Teresa to our Board of Directors,” said Elisabet de los Pinos, Chief Executive Officer of Aura Bi
  Apr 2, 2025 - $AURA
• Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
  Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC Aura Hosting Virtual Urologic Oncology Investor Event with Key Opinion Leaders Today at 4:30 pm Eastern T
  Mar 24, 2025 - $AURA
• With 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interest
  Key Insights Given the large stake in the stock by institutions, Aura Biosciences' stock price might be vulnerable to...
  Mar 24, 2025 - $AURA
• Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
  Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling Phase 2 Trial in Metastases to the Choroid Initiated Cash Position Expected to Support Operations into 2H 2026 BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology
  Mar 24, 2025 - $AURA
• Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
  Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that additional Phase 1 data evaluating bel-
  Mar 3, 2025 - $AURA
• Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
  We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
  Feb 11, 2025 - $AURA
• Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
  BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET. The live webcast of the fireside chat will be available on the “Investors & Media” pa
  Nov 26, 2024 - $AURA